BRAF V600E与TERT启动子突变联合预测复发性甲状腺乳头状癌摄碘能力丧失
该回顾性研究纳入164例结构性复发性甲状腺乳头状癌患者,分析BRAF V600E与TERT启动子突变模式与摄碘能力丧失的关系。结果显示,BRAF V600E单独突变及尤其两者共存时,与摄碘能力丧失和碘代谢基因表达受损显著相关,对RAI治疗失败具有强预测价值。
要点
- 复发性PTC中摄碘能力丧失总体发生率为62.8%(103/164)。
- BRAF V600E与TERT共存突变者摄碘能力丧失率达97.4%,显著高于无突变者的30.2%。
- BRAF V600E与TERT突变在影响摄碘能力上存在协同作用,协同指数为13.28。
核心结论
- BRAF V600E单独突变及尤其与TERT启动子突变共存,与复发性PTC摄碘能力丧失和碘代谢机制受损强烈相关,对RAI治疗失败具有稳健预测价值。
研究设计与样本
- 回顾性研究,纳入164例结构性复发性PTC患者(女性104例、男性60例),中位年龄50岁(四分位距35-62岁)。
主要发现
- 复发性PTC总体摄碘能力丧失率为62.8%(103/164)。
- BRAF V600E突变型与野生型患者摄碘能力丧失率分别为80.4%与33.9%(P<0.001),校正比值比为7.11(95%CI 3.24-16.27)。
- TERT突变型与野生型患者摄碘能力丧失率分别为89.4%与52.1%(P<0.001),校正比值比为6.89(95%CI 2.28-25.66)。
- 四组基因型中,BRAF V600E单独突变、TERT单独突变、两者共存及均无突变者的摄碘能力丧失率分别为70.3%(45/64)、55.6%(5/9)、97.4%(37/38)和30.2%(16/53),对应P值分别为<0.001、=0.251和<0.001。
- 上述四组对应比值比分别为5.39(95%CI 2.31-13.13)、2.84(95%CI 0.53-16.32)和81.04(95%CI 11.67-3559.83)。
关键数值与推荐
- BRAF V600E与TERT突变在协同影响摄碘能力上的协同指数为13.28(95%CI 1.54-114.46;P=0.019)。
- 甲状腺碘处理基因表达呈现与基因型相关的相似模式。
临床怎么用
- 对复发性PTC患者可检测BRAF V600E与TERT启动子突变,两者共存提示摄碘能力丧失风险极高,应预警RAI治疗失败可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAF V600E and TERT promoter mutations, particularly their genetic duet, are well known to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of radioactive iodine (RAI) avidity in recurrent PTC is a major cause of treatment failure and hence poor clinical outcomes. This study investigated the role of mutation patterns in loss of RAI avidity in recurrent PTC. Methods: This was a retrospective study of the relationship between loss of RAI avidity in structural recurrent PTC and the genotype patterns of BRAF V600E and TERT promoter mutations in 164 patients (104 women and 60 men) with a median age of 50 y (interquartile range, 35-62 y). Results: The overall prevalence of RAI avidity loss in recurrent PTC was 62.8% (103/164). When the cohort was divided into mutation and wild-type groups, the RAI avidity loss was 80.4% versus 33.9% (P < 0.001) in BRAF V600E versus wild-type BRAF patients, with an adjusted odds ratio of 7.11 (95% confidence interval [CI], 3.24-16.27), and 89.4% versus 52.1% (P < 0.001) in TERT mutation versus wild-type patients, with an adjusted odds ratio of 6.89 (95% CI, 2.28-25.66). When the cohort was divided into 4 genotypes, the RAI avidity loss was 70.3% (45/64), 55.6% (5/9), and 97.4% (37/38) in patients with BRAF V600E alone, TERT mutation alone, and the genetic duet of coexisting BRAF and TERT mutations, versus 30.2% (16/53) in patients with neither mutation (P < 0.001, = 0.251, and < 0.001, respectively). These corresponded to odds ratios of 5.39 (95% CI, 2.31-13.13), 2.84 (95% CI, 0.53-16.32), and 81.04 (95% CI, 11.67-3559.83), respectively. The synergy index was 13.28 (95% CI, 1.54-114.46; P = 0.019) between BRAF V600E and TERT mutation in cooperatively affecting RAI avidity. A similar genotype-associated expression pattern was observed for thyroid iodide-handling genes. Conclusion:BRAF V600E alone and, particularly, coexisting BRAF V600E and TERT promoter mutations are strongly associated with loss of RAI avidity and impairment of the iodide-metabolizing machinery in recurrent PTC, showing a robust predictive value for failure of RAI treatment of PTC.
引用
- Liu J, Liu R, Shen X, et al. The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. J Nucl Med. 2019. PMID: 31375570. doi:10.2967/jnumed.119.227652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。